Solbinsiran - Eli Lilly and Company
Alternative Names: ANGPTL3-siRNA - Eli Lilly and Company; DCR-CM1; LY-3561774Latest Information Update: 28 Apr 2024
At a glance
- Originator Dicerna Pharmaceuticals
- Developer Dicerna Pharmaceuticals; Eli Lilly and Company
- Class Antihyperlipidaemics; Cardiovascular therapies; Small interfering RNA
- Mechanism of Action ANGPTL3 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cardiovascular disorders; Dyslipidaemias
- No development reported Metabolic disorders
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Metabolic-disorders in USA (SC)
- 11 Nov 2023 Pharmacodynamics data from a preclinical trial in indication) presented at the American Heart Association Scientific Sessions (AHA-2023)
- 09 Nov 2022 Phase-II clinical trials in Cardiovascular disorders in USA (SC) (Eli Lilly and Company pipeline, November 2022)